Castle Biosciences Inc. reported that its 2025 total revenue is expected to exceed $340 million, surpassing the previously guided range of $327-335 million. The company saw a 37% increase in total test reports for its core revenue drivers, DecisionDx-Melanoma and TissueCypher, compared to 2024. At year-end 2025, cash, cash equivalents, and marketable investment securities are anticipated to total approximately $300 million. Specifically, DecisionDx-Melanoma test reports delivered in the fourth quarter of 2025 rose to 10,022 from 8,672 in the same period of 2024, while TissueCypher test reports increased to 11,803 from 6,672. The company also launched its new AdvanceAD-Tx™ test on a limited access basis in November 2025, with more than half of the participating clinician offices ordering the test within the first five weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622981-en) on January 11, 2026, and is solely responsible for the information contained therein.